Herceptin targets breast cancer stem cells

	Tweet

A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor’s growth and spread, according to a new study from the University of Michigan Comprehensive Cancer Center.
The gene, HER2, causes cancer stem cells to multiply and spread, explaining why HER2 has been linked to a more aggressive type of breast cancer and to metastatic disease, in which the cancer has spread beyond the breast, the researchers say.

Further, the drug Herceptin, which is used to treat HER2-positive breast cancer, was found to target and destroy the cancer stem cells. Results of the study appear online in the journal Oncogene.

“This work suggests that the reason drugs that target HER2, such as Herceptin and Lapatanib, are so effective in breast cancer is that they target the cancer stem cell population. This finding provides further evidence for the cancer stem cell hypothesis,” says study author Max S. Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center.

The cancer stem cell hypothesis says that tumors originate in a small number of cells, called cancer stem cells, and that these cells are responsible for fueling a tumor’s growth. These cells represent fewer than 5 percent of the cells in a tumor. Wicha’s lab was part of the team that first identified stem cells in human breast cancer in 2003.

In the current study, researchers found that breast cancer cells overexpressing the HER2 gene had four to five times more cancer stem cells, compared to HER2-negative cancers. In addition, the HER2-positive cells caused the cancer stem cells to invade surrounding tissue, suggesting that HER2 is driving the invasiveness and spread of cancer.

The researchers then looked at the drug Herceptin, which is used to treat HER2-positive breast cancer. They found Herceptin reduced the number of cancer stem cells in the HER2-positive breast cancer cell lines by 80 percent, dropping it to the same levels seen in HER2-negative cell lines.

When HER2 was not overexpressed in the cell cultures, the researchers found, the cancer stem cell population did not increase. Nor did Herceptin have any effect on the HER2-negative cells, which is consistent with how Herceptin is used in the clinic.

“We are now studying what pathways are activated by HER2 overexpression. Our hope is that we could develop inhibitors of these pathways that might be effective in targeting cancer stem cells in women whose tumors do not overexpress HER2 or those who are resistant to Herceptin,” says study author Hasan Korkaya, Ph.D., a U-M research fellow in internal medicine.

Breast cancer statistics: 184,450 Americans will be diagnosed with breast cancer this year and 40,930 will die from the disease, according to the American Cancer Society. About 20 percent of breast cancers are considered HER2-positive.

Additional authors: Amanda K. Paulson, a U-M undergraduate student, and Flora Iovino, a U-M research fellow in internal medicine

Funding: National Institutes of Health, National Cancer Institute, A. Alfred Taubman Medical Research Institute at the U-M Medical School

Reference: Oncogene, advance online publication June 30, 2008; doi: 10.1038/onc.2008.207

Resources:

* U-M Cancer AnswerLine, 800-865-1125
* Cancer’s Stem Cell Revolution

Media contact: Nicole Fawcett
E-mail:
Phone: 734-764-2220

RELATED STORIES:
Weekly dose of osteoporosis drug prevents bone loss after breast cancer treatment   Omega-3 Supplementation May Reduce Joint and Cognitive Side Effects of Breast Cancer Treatments   Teen drinking tied to breast disease   Predicting breast cancer patient outcome: MUHC researchers identify new genes   Annual screening with breast ultrasound or MRI could benefit some women   More women choosing to remove healthy breast after cancer diagnosis   Nine Questions to Help Protect Your Heart Before Surgery   Study Questions True Favorability of Rare Breast Cancer Type   Breast Cancer Treatment Heats Up   Ingredient Found in Green Tea Significantly Inhibits Breast Cancer Growth in Female Mice   Ovulation disorders linked to lower breast cancer risk   Gauging genetic breast cancer risk reassures women   Primary prevention of breast cancer: New approaches   Obesity may increase risk of triple-negative breast cancer   AACR to Honor Leading Researchers at Breast Cancer Symposium   Breast cancer screening may fuel over diagnosis   Mammography screening reduced risk for death from breast cancer by half   Future Hope for Patients with Breast Cancers Resistant to Tamoxifen   Manchester researchers announce new methods of beating breast cancer   Common transplant drug inhibits breast cancer growth, UNC laboratory study shows   Improving understanding of cell behaviour in breast cancer   Team identifies new breast cancer tumor suppressor and how it works

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]